Background: Pertuzumab, a humanized monoclonal antibody targeting human epidermal growth factor receptor (HER)-mediated signalling, has shown activity in ovarian cancer in preclinical models and in the clinic. This randomized phase II study evaluated efficacy and safety of pertuzumab in combination with carboplatin-based chemotherapy in patients with platinum-sensitive, recurrent advanced ovarian cancer.
introduction
In Europe and the USA, ovarian cancer accounts for 6% of cancer deaths [1] . The standard treatment of newly diagnosed advanced ovarian cancer (AOC) is maximal cytoreductive surgery and platinum-based chemotherapy with a taxane [2, 3] . Most patients achieve a clinical response with first-line chemotherapy comprising carboplatin and paclitaxel, but disease recurs in many cases. The majority of those with recurrent AOC have platinum-sensitive disease, and retreatment with a platinum compound achieves a response in most of these patients. However, further recurrence is inevitable and the disease ultimately proves fatal [4, 5] .
Recent efforts to improve treatment have focussed on the use of molecularly targeted agents. These include those that target the human epidermal growth factor receptor (HER) pathway, since it has been established that this plays a role in the biological behaviour and prognosis of ovarian cancer [6] [7] [8] [9] [10] [11] [12] . HER2 plays a key role, because it does not require a ligand for its activation, but rather functions as the preferred dimerization partner for ligand-activated HER1 or HER3 [13] . Furthermore, the majority of ovarian cancer cell lines proliferate in response to stimulation by epidermal growth factor and heregulin, ligands for HER1 and HER3, respectively [9, 14] .
Pertuzumab is a humanized monoclonal antibody that binds to the dimerization domain of HER2, preventing pairing of HER2 with other HER receptors known to be critical for tumour cell growth [15, 16] . By preventing dimerization of HER2, pertuzumab acts as a potent inhibitor of HER-mediated signalling pathways. Pertuzumab has demonstrated preclinical activity against various human tumour types, including HER2-negative and -positive human ovarian cancer xenograft models [17] .
In a phase II study in 123 patients with heavily pretreated, platinum-resistant AOC, pertuzumab monotherapy achieved responses in 4.3% of patients and a further 6.8% of patients experienced disease stabilization lasting at least 6 months. Median PFS was 6 weeks; for a subgroup of eight patients positive for phosphorylated HER2 ( pHER2) on fresh tumour biopsies, the median PFS was 20.9 weeks [18] .
In a randomized phase II study in 130 patients with platinum-resistant AOC, the addition of pertuzumab to gemcitabine led to a modest increase in PFS from 2.6 to 2.9 months; the objective response rates were 13.8% and 4.6% with/without pertuzumab. An increase in treatment benefit for the addition of pertuzumab was observed in patients with low HER3 mRNA expression [19] .
Synergistic cytotoxicity was demonstrated upon using an anti-HER2 monoclonal antibody in an ovarian cancer cell line treated with cisplatin [20] , as well as in breast cancer cell lines treated with a carboplatin-taxane combination [21] .
The current study was undertaken to evaluate the safety and efficacy of the addition of pertuzumab to combination chemotherapy comprising carboplatin with paclitaxel or gemcitabine in platinum-sensitive, recurrent AOC. Safety evaluation included repeated assessment of cardiac function because of reports suggesting cardiotoxicity with pertuzumab [22] .
patients and methods

study design and objectives
This multi-centre, randomized, open-label, phase II study was undertaken across 27 centres in nine countries. The primary objective was to evaluate efficacy based on progression-free survival (PFS). Secondary end points included the following: the overall response rate (ORR) as defined by Response Evaluation Criteria in Solid Tumors (RECIST) in patients with measurable disease or by CA 125 [Gynecologic Cancer Intergroup (GCIG) amendment to RECIST] in all patients; safety profile; duration of response; time to progression and overall survival (OS). An exploratory study was also conducted to assess the relevance of low HER3 mRNA expression as a predictive factor for benefit. /l, platelet count ≥100 × 10 9 /l, transfusionindependent haemoglobin ≥9 g/dl; serum bilirubin ≤ULN, alkaline phosphatase, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (or in case of liver metastases, alkaline phosphatase, AST and ALT ≤5 × ULN) and creatinine clearance ≥60 ml/ min (calculated by Jeliffe formula).
Patients with serious or uncontrolled inter-current illness, or a history or current evidence of CNS metastases, were considered ineligible, as were patients who had received prior radiotherapy or treatment with any targeted therapy, including anti-cancer vaccines. The prior cumulative dose of any anthracyclines was required to be ≤360 mg/m 2 doxorubicin (Adriamycin) or equivalent. History of congestive heart failure [New York Heart Association (NYHA) grade >2], unstable angina, evidence of transmural infarction on ECG, poorly controlled hypertension (systolic >180 mmHg and/or diastolic >100 mmHg), or haemodynamically significant valvular disease were grounds for exclusion. Furthermore, baseline left ventricular ejection fraction (LVEF) was required to be ≥50% by echocardiography (ECHO) or multiple-gated acquisition scan (MUGA). Availability of an archival formalin-fixed paraffin-embedded (FFPE) specimen was also required.
The study received ethics committee consent from all participating centres and all the patients gave informed consent.
Randomization was stratified by treatment-free interval (TFI; 6-12 months versus >12 months), measurable versus non-measurable disease, chemotherapy regimen (carboplatin-paclitaxel versus carboplatingemcitabine) and territory (Eastern Europe versus Western Europe and Canada).
efficacy analysis
All patients who received ≥1 dose of study medication were assessable for efficacy. Tumour response was assessed every 6 weeks for the first six cycles and at 12-week intervals thereafter until disease progression or 2 years after completion of the study treatment. All patients were evaluated for a CA 125 response, defined by ≥50% decrease from baseline measurement and no clinical or radiological evidence of new lesions, and in patients with measurable disease, objective response was determined according to RECIST criteria. All responses were confirmed ≥4 weeks after first PD determined by the earlier of the two events. PD was determined according to RECIST version 1.0 and/or two consecutive increases (≥1 week apart, but ≤3 months apart) of CA 125 to ≥2 × ULN or nadir (Gynecologic Cancer Intergroup Guidelines) [23] . PFS was the primary end point of the study; the primary comparative analysis was conducted 1 year after the last patient was enrolled, with the final analysis conducted 2 years after the last administered treatment. The duration of PFS was defined as the time from first-study medication to the time of documented PD or death. The duration of survival was defined as the time from first-study medication to the time of death. For patients who achieved a response, the duration of response was defined as the time from the initial response to the time of PD or death.
biomarker analysis
In an exploratory biomarker analysis, HER3 mRNA expression was measured by quantitative real-time polymerase chain reaction (qRT-PCR) in archival tumour samples. These analyses were performed at a central laboratory (Targos Molecular Pathology GmbH, Kassel, Germany) using standardized procedures. The tumour samples were supplied to the central laboratory as either FFPE tissue blocks or sections affixed to slides. Only samples containing viable tumour cells were processed and analysed. To determine the content of viable tumour cells, representative slide sections were macrodissected and stained with haematoxylin and eosin for the removal of non-tumour and necrotic tissue. The resultant tumour tissue from two slides from the same patient was then transferred to one Eppendorf tube, micro-centrifuged for a few seconds and stored at -15 to -25°C until use. RNA isolation was performed according to the High Pure RNA Paraffin Kit (Roche Diagnostic GmbH, Mannheim, Germany). The qRT-PCR assay was optimized for use on FFPE tissue, using primers that span small amplicons to minimize the effect of mRNA degradation. Furthermore, only samples producing reference gene Ct values within a pre-specified range were considered valid.
safety analysis
All adverse events (AEs) during the study and up to 28 days after the last dose of study medication were recorded and graded according to National Cancer Institute-Common Toxicity Criteria (NCI-CTC) version 3. Cardiac function was monitored at baseline and before cycles 3, 5, 7 and thereafter at 12-weekly intervals until completion of the final treatment cycle. Cardiac assessment was made by two-dimensional ECHO or, in patients whose LVEF could not be assessed by ECHO, by MUGA scan. Study-specific AEs included asymptomatic drops in LVEF of ≥10% points from baseline to <50% absolute value, all grade ≥3 AEs of cardiac origin and congestive heart failure.
statistical design
The study was designed to enrol 148 patients, to achieve 70 assessable patients per arm and provide 74% power to discern a 50% increase in median PFS [from 9 months to 13.5 months; hazard ratio (HR) = 0.67] at a one-sided level of significance of 10% (equivalent to 20% for a two-sided test), with 80% two-sided confidence intervals (CI). 
results patient and treatment characteristics
Between February and November 2006, 246 patients were screened, of whom 152 patients were recruited into the study. All patients had received one previous line of platinum-based chemotherapy; 79% had received this together with paclitaxel. A total of 75 patients were randomized to receive chemotherapy withpertuzumab (arm A), and 77 patients were randomized to receive treatment with chemotherapy alone (arm B). Three patients (one randomized to arm A and two randomized to arm B) withdrew from the study before receiving study treatment and were therefore not included in any analysis (Figure 1) .
The treatment groups were generally well balanced with respect to the baseline demographic characteristics and stratification factors (Table 1 ). An imbalance between the treatment arms was seen in the proportion of patients aged below 55 years (32% in arm A and 55% in arm B) and for the age group 55−65 years (41% in arm A and 24% in arm B). In the overall population, the median duration of TFI was 14 months with the majority of cases (60%) being >12 months. The majority of patients received paclitaxel (60%) rather than gemcitabine (40%), had measurable disease (87%) and were recruited from Western Europe and Canada.
At the time of the primary analysis, all patients had received at least six cycles of treatment, had withdrawn or died. At the final analysis, the median number of cycles of pertuzumab for patients in arm A was 11 cycles (range 1-40), and the total median dose of pertuzumab received was 5040 mg (range 420-17 220 mg). The total doses and median number of cycles administered of paclitaxel, gemcitabine and carboplatin were balanced between the treatment arms. Fifty-eight patients received pertuzumab beyond cycle 6 of treatment.
A total of 27 patients (11 from arm A; 16 from arm B) were recorded as withdrawing from the study during the first 18 weeks (Supplementary Figure S1 , available at Annals of Oncology online). Overall, the majority of discontinuations, 88% in arm A and 83.8% in arm B, were due to disease progression. Final results for the secondary end points confirmed the primary analysis that there was no significant difference between the treatment arms ( Table 2 ). Analysis of ORR and the time to response was performed at the primary analysis only.
Analysis confirmed the duration of TFI as an important prognostic factor. Patients with a shorter TFI (6-12 months) had a shorter median PFS compared with those with a longer TFI (>12 months) (30 compared with 40 weeks, 30 compared with 42 weeks in arms A and B, respectively).
biomarkers
Data on HER3 mRNA expression were available for 59/74 patients in arm A and 58/75 patients in arm B. The pretreatment characteristics of these 117 patients were similar to those of the overall study population. In view of the data on platinum-resistant patients, suggesting a role for pertuzumab in patients with low HER3 mRNA expression [11] , the exploratory analysis for this biomarker included a particular focus on the 6-12-month ( partially platinum-sensitive) subgroup. This showed no treatment effect of pertuzumab for these patients, or other subgroups, with low HER3 mRNA (Supplementary Figures S2 and S3 , available at Annals of Oncology online).
safety
A total of 149 patients were assessable for safety. One patient in arm B received some pertuzumab in error and was therefore included in arm A for the purpose of this analysis. AE comparisons were performed for events during the first six cycles of treatment as patients in arm B could not receive cytotoxic therapy beyond cycle 6 and could not cross-over to receive pertuzumab. Patients in arm A could continue to receive pertuzumab beyond six cycles up to a maximum of 52 cycles.
AEs during the first six cycles of treatment were similar in both arms (Table 3 ) but were more frequent in patients receiving gemcitabine than paclitaxel (Table 4) . Sixty-three percent of patients in arm A and 70% in arm B experienced AEs of NCI-CTC grade ≥3 severity. The most commonly reported NCI-CTC grade ≥3 AEs were haematological toxic effects, with neutropenia being the most frequent single event (Table 4 ). In the primary analysis, few patients (n = 6, 8%) experienced AEs during the pertuzumab infusion.
Pertuzumab was not associated with increased cardiac toxicity (Supplementary Table S1 , available at Annals of Oncology online); treatment-related cardiac AEs were infrequent in patients in both arms during the first six cycles of treatment (8% and 11% in arms A and B, respectively).
discussion
The potential role for pertuzumab in ovarian cancer has been evaluated extensively in recent years, and it has become clear that careful patient selection is required. The initial singleagent phase II trial suggested that patients with tumours demonstrating activated HER2 ( pHER2+) may derive most benefits [18] , and a subgroup analysis of a subsequent randomized trial of pertuzumab with gemcitabine in platinumresistant disease suggested that patients with below-median HER3 mRNA levels achieved a longer PFS from gemcitabinepertuzumab compared with gemcitabine-placebo [19] . As signalling through HER3 is a major mechanism of activation of the PI3K/AKT pathway [24] , modulation with pertuzumab may be expected to have a substantial impact on sensitivity of treated cells to cytotoxic agents such as platinum and taxanes [25] . The study reported here is the first to examine this concept in the setting of patients with platinum-sensitive ovarian cancer (platinum-free interval >6 months from previous first-line treatment). This is a heterogeneous group, since patients with a 6-12-month interval, so-called 'partially platinum-sensitive', will achieve a lower response rate and PFS with platinum-based treatment than those with an interval exceeding 12 months.
Our hypothesis was that pertuzumab may enhance the activity of platinum-based chemotherapy in relapsed ovarian cancer, and that this effect may be seen particularly in the 6-12-month subgroup, since the impact from earlier studies was greatest in the drug-resistant setting. However, our results did not indicate a benefit for pertuzumab, either in the whole population, or in the 6-12-month subgroup of 60 patients. There was no evidence for benefit in the 27 patients with low HER3 mRNA expression within the 6-12-month subgroup.
Overall efficacy in terms of the response rates for the two treatment regimens, paclitaxel-carboplatin and gemcitabinecarboplatin, were in keeping with previous publications in this disease setting [26, 27] . The median PFS in the two arms were shorter than in earlier studies, particularly compared with paclitaxel-carboplatin in the ICON-4 trial [26] . This difference may relate to differences in determination of PD (incorporation of CA 125 measurements in the current study), as well as differences in the study population. For example, the proportion of patients with a platinum-free interval >12 months was greater in the ICON-4 study (75% versus 60%, respectively) and only 40% of ICON-4 patients had received paclitaxel previously compared with 79% of patients in the current study.
Our data indicate that pertuzumab in combination with carboplatin-based chemotherapy was well tolerated, with no new safety signals, and pertuzumab did not add substantially to the toxicity burden of chemotherapy, particularly myelosuppression. Furthermore, pertuzumab was not associated with clinically significant cardiac toxicity. In summary, our results do not support further large-scale evaluation of pertuzumab in patients with AOC whose disease is sensitive to platinum-based therapy. We conclude that, in combination with chemotherapy, pertuzumab may have its main role in patients with platinum-resistant disease ( potentially through its impact on the PI3K/AKT pathway in patients with low HER3 mRNA expression). 
